Guidance
2 Information about fluocinolone acetonide intravitreal implant
2 Information about fluocinolone acetonide intravitreal implant
|
Marketing authorisation indication |
Fluocinolone acetonide intravitreal implant (Iluvien, Alimera Sciences) is indicated for 'the treatment of vision impairment associated with chronic diabetic macular oedema, (DMO) considered insufficiently responsive to available therapies'. |
|---|---|
|
Dosage in the marketing authorisation |
Fluocinolone acetonide intravitreal implant is administered through intravitreal injection. Each implant contains 0.19 mg of fluocinolone acetonide and releases fluocinolone acetonide for up to 36 months. |
|
Price |
£5,500 per implant (excluding VAT, BNF online, accessed June 2019). The company has a commercial arrangement. This makes fluocinolone acetonide intravitreal implant available to the NHS with a discount and it would have also applied to this indication if the technology had been recommended. The size of the discount is commercial in confidence. |